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piarrhea in patients with acquired immune deficiency
yndrome (AIDS) has proven to be both a diagnostic
nd treatment challenge since the discovery of the
uman immunodeficiency virus (HIV) virus more
han 30 years ago. Among the main etiologies of
iarrhea in this group of patients are infectious
gents that span the array of viruses, bacteria, proto-
oa, parasites, and fungal organisms. In many in-
tances, highly active antiretroviral therapy remains
he cornerstone of therapy for both AIDS and AIDS-
elated diarrhea, but other targeted therapies have
een developed as new pathogens are identified; how-
ver, some infections remain treatment challenges.
nce identifiable infections as well as other causes of
iarrhea are investigated and excluded, a unique en-
ity known as AIDS enteropathy can be diagnosed.
nown as an idiopathic, pathogen-negative diarrhea,
his disease has been investigated extensively. Atypi-
al viral pathogens, including HIV itself, as well as
nflammatory and immunologic responses are poten-
ial leading causes of it. Although AIDS enteropathy
an pose a diagnostic challenge so too does the treat-
ent of it. Highly active antiretroviral therapy, nutri-
ional supplementation, electrolyte replacements, tar-
eted therapy for infection if indicated, and
edications for symptom control all are key elements
n the treatment regimen. Importantly, a multidisci-
linary approach among the gastroenterologist, in-
ectious disease physician, HIV specialists, oncology,
nd surgery is necessary for many patients.
ore than 100 million people worldwide currently
are infected with the human immunodeficiency
irus (HIV). Moreover, many have perished from this
evastating disease. Beginning in the mid-1980s, a new
isease entity, which ultimately would be named the
cquired immune deficiency syndrome (AIDS), was de-
cribed among patients in rural Uganda, Zaire, Tanzania,nd in the United States. Because major symptom com-
lexes involved the digestive tract with profound weight
oss, malnutrition, and severe watery diarrhea, this dis-
ase was named by the indigenous African population
lim disease. African patients with this poorly under-
tood illness literally wasted away. Serwadda et al1 re-
orted that slim disease appeared to occur predomi-
antly in a heterosexual promiscuous population in
frica. At that time, they believed there were no clear
ndications to implicate other modes of transmission
uch as insect vectors or injection drug use.
An uncertain, but high, percentage of HIV-infected
atients worldwide initially present with or ultimately
evelop diarrhea with or without highly active antiretro-
iral therapy (HAART). Currently, substantial diarrhea
ccurs in about 50% of the HIV-infected individuals in
he United States. In the developing world, however,
iarrhea may occur with a much higher prevalence, in as
any as 80% of HIV-infected individuals. Specific enteric
athogens can be isolated (if patients undergo exhaustive
nd intensive standard gastrointestinal [GI] evaluation)
n most individuals with severe diarrhea. Currently, in
reas of the world with access to sophisticated endo-
copic evaluation, specific but atypical pathogens likely
ill be found in nearly 50% of patients with severe stool-
tudy–negative diarrhea. Indeed, colonoscopy with intu-
ation and biopsy of the terminal ileum together with
ndoscopy of the upper GI tract successfully identifies
athogens in 46% of patients with previously termed
diopathic diarrhea (Table 1).2 However, not every patient
Abbreviations used in this paper: AIDS, acquired immune deficiency
yndrome; CMV, cytomegalovirus; GALT, gut-associated lymphoid tis-
ue; GI, gastrointestinal; HAART, highly active antiretroviral therapy;
IV, human immunodeficiency virus; MAC, Mycobacterium avium com-
lex; OI, opportunistic infection; TB, tuberculosis.
© 2009 by the AGA Institute
0016-5085/09/$36.00doi:10.1053/j.gastro.2008.12.073
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May 2009 AIDS ENTEROPATHY 1953ith HIV-associated diarrhea needs a complete endo-
copic evaluation. A full endoscopic work-up is necessary
n patients with a functionally disabling diarrhea in
hich the etiology is unclear.
In many patients, diarrhea leads to a diminished qual-
ty of life. Small-bowel mucosal diseases routinely are
ssociated with profound malnutrition and are a com-
on manifestation of the HIV disease in the developing
orld. Diarrhea is an early and pervasive manifestation of
IV disease and is associated with increased morbidity
nd mortality. Diarrhea also substantially increases
ealth care costs for many patients, particularly those
ith severe secretory diarrhea and malabsorption/malnu-
rition necessitating repeat hospitalizations.
Clinical presentations vary among patients with HIV-
ssociated diarrhea depending on the principal area of
he GI tract involved. Small-bowel diarrhea tends to pro-
uce large, bulky, postprandial stools. If patients with
mall-bowel diarrhea fast from nutrients they do not
ave significant amounts of diarrhea. Conversely, after a
eal, patients with small-bowel diarrhea report that al-
ost immediately they have postprandial paraumbilical
bdominal pain and voluminous diarrhea. Weight loss is
haracteristic of small-bowel diarrhea. On the other
and, large intestinal diarrhea, so-called colitic diarrhea, is
ssociated with frequent, small-volume stools. These pa-
ients do not commonly become dehydrated. Colonic
iarrhea also may be associated with the presence of
isible blood and mucous. These patients with large-
owel diarrhea often have lower-quadrant abdominal
ain and/or will have the sensation of rectal urgency. In
any instances it is difficult to distinguish between
arge- and small-bowel diarrhea based on clinical presen-
ation alone, thus highlighting the need for further and
ore exhaustive diagnostic evaluation.
Idiopathic AIDS Enteropathy
Over the past 2 decades a well-defined subset of
IV/AIDS patients with profound diarrhea, malnutri-
ion, and wasting, with no infectious pathogen identified
s the causative agent, has emerged. In 1987, Kotler et al3
able 1. Prospective Endoscopic Evaluation of 71 Patients
With Stool-Study–Negative AIDS Diarrhea
Procedures Sensitivity
lexible sigmoidoscopy 21/37 (57%)
uodenum 17/37 (46%)
uodenum  flexible sigmoidoscopy 29/37 (78%)
uodenum  full colonoscopy 34/37 (92%)
ull colonoscopy 28/37 (76%)
ull colonoscopy  ileum 35/37 (95%)
olonoscopy  ileum  duodenum 37/37 (100%)
OTE. Reprinted from Kearney DL, Koch J., Cello JP. Am J Gastro
999;94:596–602.oted alterations in intestinal plasma cells of AIDS pa- Sients without identifiable (at that point in time) intes-
inal pathogens (Figure 1). In HIV-infected patients with
IDS-related complex or fully expressed AIDS, the mean
illus/height and mean villus/crypt ratios were signifi-
antly lower than those of normal controls (Figure 2). By
sing immunofluorescence staining, the researchers ob-
erved a decrease in immunoglobulin (Ig)A plasma cells
nd a relative increase in IgM plasma cells in the small
owel and in the colon. There also was decreased quan-
itative plasma cell fluorescence in samples that were
tained for IgA and IgM, implying less cytoplasmic im-
unoglobulin per cell. However, the depletion of IgA
rom plasma cells did not always correlate with altered
erum IgA concentrations. Kotler et al3 also noted that
he lymphoid depletion in patients with AIDS might be
atchy and might involve many cells in addition to the
lasma cells.
Initial speculation that HIV itself was infecting cells
irectly, both within the epithelium and the lamina pro-
ria, has been tempered by the identification of atypical
iruses that rarely were searched for in the GI tract of
atients with AIDS-related diarrhea. In 1998, Cunning-
am et al4 first identified rotaviruses and adenoviruses by
nzyme-linked immunosorbent assay, electron micros-
opy, and/or cell culture analyses. These 2 viruses were
ound in more than 50% of HIV-positive symptomatic
atients with diarrhea, but in less than 15% of HIV-
egative patients, and in less than 20% of HIV-positive
symptomatic patients without diarrhea. It appeared,
herefore, that these viruses occasionally were associated
ith a high excretion rate in HIV-infected patients with
iarrhea and might be associated with acute episodes or
elapses of diarrhea. Cunningham et al4 also postulated
igure 1. Biopsy of small bowel from a patient with AIDS and patho-
en-negative diarrhea. Note the prominent villus atrophy, crypt archi-
ectural distortion, decrease in crypt/villus ratio, and the significant influx
f lymphocytes within the lamina propria. Figure courtesy of Dr James
. Grenert from the Department of Pathology, University of California,
an Francisco.
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1954 CELLO AND DAY GASTROENTEROLOGY Vol. 136, No. 6hat there may be additional, yet to be identified, patho-
ens in patients with chronic or relapsing acute diarrhea.
Grohmann et al,5 from the Centers for Disease Control,
eported in 1993 on the prevalence of a wide range of
nteric viruses in HIV-infected patients with and without
iarrhea. Sixty-five HIV-positive patients were grouped into
hose with diarrhea and those without diarrhea. Adenovi-
us, astrovirus, and picobiranvirus, but not chronovirus,
aliciviridae, or featureless small round viruses were noted
n the stools of HIV-positive patients with diarrhea com-
ared with HIV-infected patients without diarrhea. Overall,
5% of the fecal specimens in patients with AIDS and
efractory diarrhea harbored 1 or more of these viruses, pompared with only 12% of the stools of patients without
iarrhea (Table 2). Thus, studies and reports of so-called
IDS enteropathy always should be tempered by the reality
hat these viruses, as well as other infectious agents, ulti-
ately may be found in patients with so-called idiopathic
IDS-related diarrhea. One need only recall belatedly iden-
ified pathogens such as mycobacterium-avium complex,
ryptosporidium, or microsporidium in patients with pre-
iously termed idiopathic AIDS diarrhea.
Recognizing the real potential for unsuspected or un-
dentified pathogens in the bowel, many investigators
ave found that HIV itself infects enterocytes, lamina
Figure 2. Comparison of (A) mean villus/crypt ra-
tio, (B) mean villus/height ratio, (C) and mean crypt
depth among AIDS patients with and without diar-
rhea and normal controls. ARC, AIDS-related com-
plex. Reprinted with permission from Greenson JK
et al.79 AIDS enteropathy: occult enteric infections
and duodenal mucosal alterations in chronic diar-
rhea. Ann Intern Med 1991;141:366–327.ropria cells, and submucosa. Nelson et al6 in 1988,
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May 2009 AIDS ENTEROPATHY 1955sing in situ hybridization of biopsied specimens ob-
ained from the rectum and duodenum, showed HIV-
nfected cells in both the base of the crypts and within
he lamina propria. They postulated that the association
f in situ labeling of HIV RNA in argentaffin cells
trongly suggested that enterochromaffin cells derive
rom the neural crest tissue and may in fact be among the
rimary target cells of HIV. Along the same lines, Batman
t al7 described jejunal enteropathy associated with HIV;
he degree of villus atrophy in the jejunal mucosa was
stimated using a Widal eye piece graticule. Jejunal villus
nterocytes showed mild, nonspecific abnormalities with
rypt hyperplasia recurring in all stages of HIV disease,
ven in the absence of pathogens. They suggested that
he pathogenesis of villus atrophy was actually an im-
une reaction within the lamina propria against cells
nfected with HIV. Delezay et al8 reported the findings
rom an in vitro study on the differentiation of an epi-
helial cell clone HT-29-D4. They noted that HIV im-
aired cellular differentiation of both barrier function
nd sodium-glucose co-transport. In this epithelial cell
ine, HIV massively disrupted microtubules, revealed by
-tubulin indirect immunofluorescence staining. The in-
estigators suggested that HIV perturbs intestinal func-
ion with or without infecting the epithelial cells them-
elves.
Once opportunistic disorders are excluded in patients
ith refractory diarrhea, HIV enteropathy can exist in a
able 2. Viral Agents Detected in 222 Fecal Specimens From
Present
Diarrhea, n (%)
Virus
Specimens
(N  109)
Patients
(N  65)
denovirus 10 (9) 10 (15)
strovirusb 13 (12) 9 (14)
oronavirus-like particle 3 (3) 2 (3)
mall round viruses
SRSVc 4 (4) 4 (6)
Calicivirusc 2 (2) 2 (3)
Featureless 3 (3) 2 (3)
icobirnavirusd 10 (9) 6 (9)
otale 38 (35) 24 (37)
Infection with 1 virus 31 (28) —
Mixed infectionf 7 (6) —
OTE. A total of 110 patients contributed 222 specimens: 59 patients
he patients who provided more than 1 specimen were those enrolled
case patients) or a 3-month period without diarrhea (controls).
The 2-tailed P value was calculated by the Fisher exact test.
Three patients had acute episodes of astrovirus-associated diarrhea
SRSVs, or Norwalk-like viruses, are considered to be members of th
aliciviridae were associated marginally with diarrhea (P  .062 for
The 2 patients without diarrhea who shed picobirnavirus at different
atient included as both a case patient and control.
The total number of specimens with virus present as a single or mixe
The mixed infections consisted of 4 cases of adenovirus and astro
denovirus and coronavirus-like particle.mall but definite percentage of the population. Batman wt al9 have studied crypt, stem, and transit cell prolifera-
ion. In a study on the kinetics of stem and transit cell
ines, they noted definite villus atrophy induced by both
icrosporidia and HIV itself. Both these infections pro-
oke crypt cell hypertrophy, including encroachment of
he crypt cells onto the villi by stimulating cell mitoses in
oth stem and transit cells. Dandekar10 clarified the
athogenesis of HIV disease in the GI tract, noting that
he gut-associated lymphoid tissue (GALT) was clearly an
arly site of HIV replication and CD4 T-cell depletion.
dditional studies have supported that HIV destroys
ALT in the early stages of HIV infection.11 Initiation of
AART did not lead to complete suppression of viral
eplication and there was only partial restoration of
D4 T-cells in the GALT, compared with the peripheral
lood. It appeared that persistent HIV replication in
ALT leads to crypt alterations and maintenance of the
IV reservoirs.
Knox et al12 described the functional disruption of the
I tract caused by HIV in 2000. Among 671 patients with
IV infection, 39% had diarrhea; stool pathogens were
dentified in only 12% of these patients. Despite this, 48%
f all patients had an abnormal D-xylose test, 22.5% had
orderline or low serum B-12 levels, and 7.2% had a
epressed albumin level. The investigators suggested that
bnormalities of the GI tract are common even in the era
f modern HAART, so the clinician therefore carefully
ust exclude identifiable pathogens, even in patients
-Infected Patients, According to Whether Diarrhea Was
No diarrhea, n (%) P valuea
pecimens
N  113)
Patients
(N  65) Specimens Patients
3 (3) 3 (5) .047 .076
2 (2) 2 (3) .003 .054
2 (2) 2 (3) .679 1.00
1 (1) 1 (2) .206 .365
0 0 .24 .496
3 (3) 3 (5) .621 .619
2 (2) 1 (2) .017 .115
13 (12) 8 (12) .001 .002
13 (12) — .002 —
0 — .006 —
ided only 1 specimen and 51 patients provided 2 or more specimens.
in the study who, at different times, had either new onset of diarrhea
ore than one occasion.
ily Caliciviridae along with human caliciviruses. Taken together, the
mens, P  .115 for patients).
had picobirnavirus-associated diarrhea. Only in this category was a
ction. Some patients were infected with more than one type of virus.
, 2 cases of calicivirus and coronavirus-like particle, and 1 case ofHIV
S
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virusho are on HAART. Monkemuller et al13 noted that since
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1956 CELLO AND DAY GASTROENTEROLOGY Vol. 136, No. 6he widespread use of HAART, there has been a dramatic
ecrease in the prevalence of identifiable opportunistic
nfections of the GI tract, but that opportunistic infec-
ions still occurred. They examined a population of 294
atients treated with HAART; 88% of the patients were
en, with a mean age of 36.5 years. In this study patients
ad a mean CD4 T-cell count of 64 and a mean RNA
iral load of 40,357 copies per mL. Despite all being
reated with HAART, 9% of patients had identifiable
pportunistic disorders of the GI tract. In careful ques-
ioning, however, they identified approximately 40% of
hese patients with new or persistent opportunistic dis-
rders of the GI tract as being likely or definitely non-
ompliant with administered HAART. Thus, GI oppor-
unistic disorders still can occur in HIV-positive patients,
ncluding those allegedly taking HAART and especially in
hose with low CD4 T-cell counts and high HIV viral
oads. Unfortunately, these opportunistic disorders still
an occur in patients with near-normal CD4 T-cell
ounts and low HIV viral loads.
Thus, HIV enteropathy is associated with increases in
nflammation and immune activation and decreases in
ucosal repair and regeneration—these all contribute to
he presence of HIV enteropathy. In 2008, Sankaran et
l11 highlighted once again the importance of GALT as
n early target for HIV infection and the site of severe
D4 T-cell depletion. They noted that viral replication
ccurred very early in primary HIV infection in the GALT
D4 T cells and macrophages. There was also a de-
rease in the expression levels of genes that regulate
pithelial barrier maintenance and digestive metabolic
unction. These changes coincided with a decrease in
ranscription of immune activation, inflammation, and
poptosis-associated genes. Consequently, HIV infection
n GALT occurs at both a molecular and a cellular level
ven before seroconversion.
Although HIV enteropathy encompasses an idiopathic,
athogen-negative diarrhea, there is an array of opportu-
istic infections (OIs) that invade the GI tracts of pa-
ients with advanced HIV. GI OIs include a complex
ilieu of bacteria, fungus, viruses, and protozoa that hypically exert their devastating effects when a patient’s
D4 T-cell count decreases to less than 200 cells/L
Figure 3). The study of GI OIs has undergone an aston-
shing transformation over the past 25 years, and has
een marked by periods of remarkable discovery and
nnovation in terms of identifying new pathogens and
uitable treatments. Similar to the evolving treatment of
hese infections, the role of the gastroenterologist under
hese circumstances has changed over time as well. In
any cases, a multidisciplinary approach among gastro-
nterology, infectious disease, HIV specialists, oncology,
nd surgery not only is encouraged, but in many cases is
equired for treating HIV patients with GI OIs.
The advent of HAART revolutionized the treatment of
IV and resulted in striking declines in HIV-related in-
ections and associated mortality.14 In addition, HAART
arked a sustained and continued decline in the inci-
ence and prevalence of GI OIs.15 This dramatic decline
as illustrated superbly by Monkemuller et al15 in a
rospective study at the University of Alabama in Bir-
ingham. In examining 166 AIDS patients undergoing
ual endoscopy for GI complaints at 3 time periods in
he 1990s (2-year intervals), they discovered the incidence
f GI OIs decreased from a peak of 69% to a nadir of 13%,
hereas at the same time HAART use in their patients
ncreased from 37% to 87%. Several multifactor theories
ave been proposed to explain this decline of GI OIs. One
s that the re-establishment of the patient’s own natural
mmunity, with the repopulation of T cells in the enteric
ucosa, combats various opportunistic pathogens that it
reviously could not fight. A second explanation may be
he direct effect of the HAART regimen itself on specific
athogens. Within combinational HAART, protease in-
ibitors have been observed both in vivo and in vitro to
ave inhibitory properties on specific organisms via the
egradation of aspartyl proteases.16,17 Regardless of the
echanism, HAART has had extraordinary success in
reating HIV-associated GI OIs since its introduction.
The success of HAART spans across an entire assort-
ent of GI OIs. For example, multiple studies uniformly
Figure 3. Association between gastrointestinal
infections as a result of a specific pathogen and
CD4 T-cell count ranges in HIV-positive
patients.ave shown a decrease in the incidence of cryptospo-
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May 2009 AIDS ENTEROPATHY 1957idium and microsporidium in response to HAART.18,19
ikewise, an influential 1998 study by Carr et al20 discov-
red that HIV patients infected with Cryptosporidium par-
um or Enterocytozoon bieneusi (most of which had failed
revious antimicrobial therapy) had a full clinical, histo-
ogic, and microbiological response to HAART. In addi-
ion, a majority of patients remained symptom free for
ore than 1 year and those with recurrent symptoms had
eclining CD4 T-cell counts. However, this interplay
etween HAART and the treatment of GI OIs is not
imited to parasitic and fungal organisms. This story was
nraveled eloquently in several studies on the treatment
f patients with cytomegalovirus (CMV) infections. HIV
atients on combination HAART consistently have
reater rates of survival, compared with HAART-naive
atients, even when adjusting for CMV therapy.21 Ac-
ordingly, the profound effect of HAART on treating GI
Is is unquestionable and should be front-line therapy
or many GI OIs. Although the effects of HAART are
ompelling, some researchers have noted the occurrence
f GI OIs despite the use of HAART.13 In this subset of
atients, factors such as medication noncompliance, re-
istant strains of HIV, late initiation of HAART, or poor
ioavailability of HAART all could have a role in its
nability to always treat OIs. These situations underscore
he need for continued targeted therapy of OIs in some
ircumstances despite the use of HAART (Table 3).
Treatment of OIs of the GI Tract
Although the rates of GI parasitic infections have
eclined over time, 3 pathogens (Cryptosporidia, Isospora, and
yclospora) continue to contribute to the morbidity and
ortality among AIDS patients with diarrhea. Of these,
ryptosporidiosis has been a challenge to treat over the
ears. Its intracellular location within enterocytes and in-
ate resistance has been responsible for this dilemma.22,23
lthough HAART has reduced the incidence of cryptospo-
idiosis among HIV patients, leading to complete resolution
f diarrhea and pathogen eradication on many occa-
ions,20,24 unfortunately, in many parts of the world patient
ccess to HAART is limited.
Over the years, 2 main therapies have emerged as
otential treatments for cryptosporidiosis: nitazoxanide
nd paromomycin. However, clinical studies on both
hese agents have been limited by their small sample
izes, the lack of enrollment of patients with HIV, the
mall number of randomized controlled trials, and con-
icting results. A 2007 Cochrane meta-analysis at-
empted to address and resolve these issues.25 The meta-
nalysis of studies of nitazoxanide therapy compared
ith placebo indicated that nitazoxanide effectively cured
he parasitic infection in patients overall, but the data for
atients with HIV was not statistically significant; HIV
atients tended to have less resolution of their diarrheal
llness. Interestingly, the only 2 randomized studies that
ere included in this meta-analysis and that examined sitazoxanide therapy in HIV patients had several striking
ifferences. An initial study by Rossignol et al26 in 1998
howed that HIV patients with cryptosporidial diarrhea
nd CD4 T-cell counts of 50 cells/L or more had a
reater than 60% cure rate compared with placebo after 2
eeks of nitazoxanide therapy. Conversely, 3 years later,
madi et al27 examined children with AIDS and found
hat a short, 3-day course of nitazoxanide therapy re-
ulted in reduced stool volume, increased fecal oocyte
learance, and improved mortality in HIV-negative chil-
ren, but did not show similar results for HIV-positive
hildren. One could argue that the treatment duration of
weeks compared with 3 days as well as the patient
opulation (adult vs pediatric) makes comparing and
rawing cohesive conclusions from these 2 studies chal-
enging. Fueling this debate was a 2006 multicenter pro-
pective evaluation of 365 AIDS patients with cryptospo-
idiosis treated with nitazoxanide. This has been the
argest study to date on nitazoxanide therapy for HIV-
elated cryptosporidiosis and more than 94% of the study
ubjects were adults. This study showed that 59% of
atients achieved a clinical response with culture-nega-
ive stool cultures while on nitazoxanide therapy and
hat patients with higher CD4 T-cell counts were more
ikely to achieve a continued clinical response.28 Further,
arger randomized placebo-controlled trials with nitazox-
nide therapy in HIV patients are warranted before de-
nitive recommendations for treatment can be made;
lthough current evidence appears to support the use of
itazoxanide in HIV adult patients for a prolonged
ourse with a better response rate observed in patients
ith more robust cellular immunity.
Along the same lines, paromomycin has had equivocal
esults over time. Studies of paromomycin have included
ar fewer HIV patients compared with studies of nitazox-
nide. The 2007 Cochrane meta-analysis showed a slight
rend toward effective treatment using paromomycin,
ut the overall relative risks for decreased stool frequency
nd oocyte clearance were modest and not statistically
ignificant.25 Compared with randomized trials for nita-
oxanide, paromomycin therapy had appreciably more
isappointing and contradictory results. Hewitt et al29
howed that paromomycin therapy did not result in
ore partial or complete clinical responses than placebo
nd concluded that paromomycin was ineffective in
reating symptomatic cryptosporidial diarrheal disease.
n earlier study by White et al30 reported that paromo-
ycin might result in some clinical improvements in
atients with AIDS cryptosporidial diarrhea, but these
mprovements were short lived and associated with a
igh relapse rate, approaching 33% once therapy was
iscontinued. Unfortunately, there are no trials compar-
ng paromomycin and nitazoxanide therapies directly.
hus, paromomycin might have some efficacy in treating
ymptomatic cryptosporidial diarrhea, but it appears to
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1958 CELLO AND DAY GASTROENTEROLOGY Vol. 136, No. 6able 3. Specific Treatment Regimens for Gastrointestinal Opportunistic Infections in HIV-Infected Patients
Infection Initial treatment Alternative treatment(s)
rotozoa
Cryptosporidia Combination antiretroviral therapy Nitazoxanide 500–1000 mg PO BID for 2 wk
Paromomycin 25–35 mg/kg PO daily for 2 wk
Paromomycin 1 g PO BID  Azithromycin 600
mg PO daily for 4 wk
Cyclospora cayetanensis Trimethoprim/sulfamethoxazole 160/800 mg PO
QID for 1 wka
Ciprofloxacin 500 mg PO BID for 1 wk
Nitazoxanide 500 mg PO BID for 3 days
Isospora belli Trimethoprim/sulfamethoxazole 160/800 mg PO
QID for 10 daysa
Ciprofloxacin 500 mg PO BID for 1 wk
Nitazoxanide 500 mg PO BID for 3 days
Pyrimethamine 50–75 mg PO daily for 3–4 wk
ungus
Microsporidia
Encephalitozoan intestinalis Combination antiretroviral therapy  Albendazole
400 mg PO BIDb
Enterocytozoon bieneusi Combination antiretroviral therapy Fumagillin 60 mg PO daily for 2 wkc
Histoplasma capsulatum Initial phased: liposomal amphotericin B 3 mg/kg
IV daily for 2 weeks
Continuation phasee: itraconazole 200 mg PO
TID for 3 days, then BID for 12 mo
Initial phased: amphotericin B deoxycholate
0.7 mg/kg IV daily for 2 wk
Cryptococcus Initial phase: Amphotericin B deoxycholate 0.7
mg/kg IV daily (or liposomal amphotericin B
4–6 mg/kg IV daily)  Flucytosine 25 mg/kg
PO QID for 2 wk
Continuation phase: Fluconazole 400 mg PO
daily for 8 wk
Initial phase: Amphotericin B  Fluconazole
400 mg PO/IV daily for 2 wk
Amphotericin B alone
Fluconazole 400–800 mg PO/IV daily 
Flucytosine 25 mg/kg PO QID for 4–6 wk
Continuation phase: Itraconazole 200 mg PO
BID for 8 wk
irus
CMV Combination antiretroviral therapy  Ganciclovir
5 mg/kg IV BID for 3–6 wk OR
Foscarnet 90 mg/kg IV BID for 3–6 wk
Valganciclovir 900 mg PO BID for 3–4 wk or
until resolution of symptomsf
acteria
MAC Clarithromycin 500 mg PO BID  Ethambutol 15
mg/kg PO daily (Rifabutin 300 mg PO daily)
See 2008 NIH/CDC/HIVMA/IDSA guidelines
for alternative regimens and additional
fourth drug options
Mycobacterium tuberculosis Initial phase: Isoniazid 5 mg/kg PO daily 
Rifampin 10 mg/kg PO daily (or Rifabutin 300
mg PO daily)  Pyrazinamide 15–30 mg/kg PO
daily  Ethambutol 15–25 mg/kg PO daily for
2 mo
Continuation phase: Isoniazid 5 mg/kg PO daily
 Rifampin 10 mg/kg PO daily (or Rifabutin
300 mg PO daily) for 6 mo
See 2008 NIH/CDC/HIVMA/IDSA guidelines
for alternative regimens, treatment for
multidrug-resistant TB, patients with liver
disease, and/or interactions with HAART
Campylobacter jejuni Ciprofloxacin 500 mg PO BID for 1–2 wkg Azithromycin 500 mg PO daily for 1–2 wkg
Salmonella Ciprofloxacin 500–750 mg PO BID for 1–6 wkh Trimethoprim/sulfamethoxazole 160/800 mg
PO BID for 1–6 wkh
Shigella Ciprofloxacin 500 mg PO BID for 1–2 wkg Trimethoprim/sulfamethoxazole 160/800 mg
PO BID for 1 wk
Azithromycin 500 mg PO on day 1, then 250
mg PO daily for 4 days
ID, twice a day; CDC, Centers for Disease Control; HIVMA, HIV Medicine Association; IDSA, Infectious Diseases Society of America; NIH,
ational Institutes of Health; PO, per os (by mouth); QID, 4 times a day; TID, 3 times a day.
odified from Table 2 of the 2008 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.37
May require secondary prophylaxis with trimethoprim/sulfamethoxazole 160/800 mg PO three times weekly in patients with CD 4 T-cell counts
200 cells/L.
Continue until CD4 T-cell count 200 cells/uL for more than 6 months after initiation of HAART.
Currently not approved for use in the United States.
Begin with Amphotericin B for initial phase if infection is severely disseminated or patient is critically ill.
Drug regimen can be used for both the initial and continuation phases if disseminated disease is not severe.
Can be considered initial therapy if symptoms are not severe enough to interfere with oral absorption.
Patients with mild/moderate disease are treated for 1 week, and patients with bacteremia are treated for 2 weeks.
Patients with CD4 T-cell count 200 cells/L are treated for 1–2 weeks, and patients with CD4 T-cell count 200 cells/L are treated for 2–6
eeks.
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May 2009 AIDS ENTEROPATHY 1959e less consistent than nitazoxanide and does not always
ead to a sustained response.
A plethora of other agents have been studied for the
reatment of HIV cryptosporidial diarrhea. Spiramycin,
ovine dialyzable leukocyte extract, and bovine hyperim-
une colostrums all have been investigated rigorously in
andomized controlled clinical trials and also were in-
luded in the Cochrane meta-analysis.25 All 3 drugs, when
ompared with placebo, were ineffective in either reduc-
ng stool volume or curing patients of the parasite infec-
ion. Clarithromycin, octreotide, and atovaquone all have
een tried, with limited success.31,32 On the horizon, a
ombination of paromomycin plus azithromycin,33 as
ell as using rifaximin23,34,35 alone, have shown encour-
ging results in improving symptoms and decreasing
ryptosporidial oocyte excretion, especially in HIV pa-
ients refractory to other therapies. Thus, current evi-
ence strongly supports the use of HAART (with a pro-
ease inhibitor as part of the regimen) as initial therapy
or patients with cryptosporidiosis; HAART clearly has
hown persistent clinical effects and the ability to cure
arasite infections in many HIV-infected patients. For
atients who continue to have severe diarrheal disease
espite HAART and improved CD4 T-cell function the
ddition of nitazoxanide therapy should be considered;
owever, nitazoxanide therapy alone is inappropriate
ithout HAART.36
The treatment options for isosporiasis are more de-
nitive. The mainstay of therapy is trimethoprim/sulfa-
ethoxazole (160/800 mg) orally 4 times a day for 10
ays.37 Given the high relapse rate of nearly 50%, this
egimen usually is followed by secondary prophylaxis—
specially in patients for whom HAART cannot be started
r when CD4 T-cell counts continue to remain less
han 200 cells/L. Although ciprofloxacin is less effective,
hen compared directly with trimethoprim/sulfame-
hoxazole, it does have a success rate greater than 70% in
esolving symptoms and curing HIV patients of isospo-
iasis infection.38 Alternative regimens for patients who
annot tolerate or have failed trimethoprim/sulfame-
hoxazole and/or ciprofloxacin include nitazoxanide or
yrimethamine.39,40
Similarly, cyclosporiasis is treated with trimethoprim/
ulfamethoxazole (160/800 mg) orally 4 times a day for 7
ays with similar efficacy as isosporiasis.41,42 Again, sec-
ndary prophylaxis with trimethoprim/sulfamethoxazole
ay be necessary in patients not on HAART or with low
D4 T-cell counts. Other less-effective regimens in-
lude ciprofloxacin and nitazoxanide.38,40
Microsporidium, now reclassified as a fungus, has long
een associated with infection of the small bowel in patients
ith advanced HIV. Encephalitozoan intestinalis and Enterocy-
ozoon bieneusi are the 2 most prevalent species encountered
n immunocompromised patients. Similar to the treatment
f cryptosporidiosis, restoration of the patient’s innate im-
une system with HAART is of paramount importance in mreating HIV patients who have microsporidium infections.
AART alone can result in a cessation of diarrhea, consid-
rable weight gain in wasting patients, and a complete
radication of the organism, determined through microbi-
logical and histologic analyses, in many patients.19,20,43 In
ddition to immune reconstitution, several therapies have
volved over time to treat microsporidium. Treatment for
ncephalitozoan intestinalis has remained unchanged for the
ast several years and includes albendazole, a benzimidazole
hat inhibits tubulin polymerization. Albendazole therapy
or Encephalitozoan intestinalis consistently results in com-
lete organism eradication in HIV-positive patients.44,45
In contrast, Enterocytozoon bieneusi has proven to be a
ore challenging and difficult entity to treat. Some
uccess has been achieved with albendazole, although
athogen suppression is incomplete and inconsistent.46
umagillin, an antibiotic with anti-angiogenic properties,
howed encouraging results in early studies in improving
IV symptoms and fecal clearance of the organism.47
nfortunately, high rates of bone marrow toxicity have
imited the use of this drug within the United States and
t has never received Food and Drug Administration
pproval. Consequently, an analogue, TNP-470, was de-
eloped, but showed success only in in vivo and in vitro
tudies and has not made its way to human clinical trials
or the treatment of Enterocytozoon bieneusi.48 A host of
ther agents either have had limited success or disap-
ointing results. Studies of these potential agents are
imited by the fact that their efficacy was shown only in
ase reports or a small series of patients, or only in in
itro or in vivo studies. These therapies include nitazox-
nide, atovaquone, itraconazole, metronidazole, octreo-
ide, thalidomide, and trimethoprim/sulfamethoxazole.43
verall, once the diagnosis of microsporidium is con-
rmed, treatment should begin promptly with combi-
ation HAART as well as electrolyte replacement and
ymptom management. Encephalitozoan intestinalis can be
reated successfully with albendazole, although at the
oment there is no available effective therapy in the
nited States for Enterocytozoon bieneusi.
There are an array of other fungal organisms that can
nfect the GI tract and cause severe morbidity andmortality.
hese organisms usually are rare, geographically distinct,
nd mostly occur when disease is disseminated. Fungal OIs
hat may be encountered in the United States include his-
oplasmosis and cryptococcosis. Inmany cases, GI signs and
ymptoms are obscured by widespread infection (usually of
he pulmonary or central nervous systems); it is unusual for
hese infections to be localized specifically to the GI tract,
lthough this has been reported.49,50 Given the strong in-
eraction between systemic disease and GI involvement, the
ainstay of therapy for these infections focuses on treat-
ent for disseminated disease. GI and systemic infections
re similar in that they are treated originally with an induc-
ion phase to control clinical signs followed by a prolonged
aintenance phase for relapse prevention. Commonly, am-
p
l
n
t
n
c
t
e
C
t
s
c
u
1
p
r
d
v
t
c
p
r
c
w
s
d
t
i
t
o
i
s
b
r
c
C
d
l
t
c
t
m
t
A
s
p
m
c
g
t
t
U
s
r
i
w
t
m
s
t
l
s
t
p
i
p
n
r
w
G
f
s
c
i
u
p
s
a
L
w
o
o
w
H
n
t
t
m
p
l
w
C
m
d
r
(
d
d
a
a
d
t
o
t
1960 CELLO AND DAY GASTROENTEROLOGY Vol. 136, No. 6hotericin B (either the deoxycholate or liposomal formu-
ation) is used in the induction phase followed by mainte-
ance therapy either with fluconazole or itraconazole. Long-
erm maintenance therapy could be required for patients
ot on HAART or with persistently low CD4 T-cell
ounts. Lastly, it is important to treat GI OIs by restoring
he patient’s immune system with HAART.
Viral Pathogens of the GI Tract
Several viruses have been implicated in HIV
sophagitis/enteritis/colitis over the years, most notably
MV. The vast majority of patients with viral pathogens
hat infect the GI tract are treated with HAART as well as
upportive care for electrolyte imbalances and symptom
ontrol. However, CMV GI disease has proven to be a
nique challenge compared with other viruses. Nearly
5% of CMV infections occur in the GI tract51 and the
revalence of CMV colitis in HIV patients with diarrhea
anges from 13% to 45%.52,53 Although there are some
ata available on the treatment of CMV GI disease, the
ast majority of studies have focused on CMV retinitis;
reatment recommendations for CMV GI disease have
ome from these studies. It is important to treat CMV
romptly, given its poor prognosis and high rates of
ecurrence.
Treatment for CMV infection of the GI tract should
ommence with either ganciclovir or foscarnet for 3–6
eeks. This time frame for therapy can vary and patients
hould be monitored for signs of clinical improvement to
etermine the length of treatment time required. Clinical
rials support the use of either ganciclovir or foscarnet as
nitial treatment54,55; an open, randomized study of pa-
ients with CMV GI disease treated with either foscarnet
r ganciclovir showed that either drug led to similar
mprovements in clinical symptoms, resolution of endo-
copic findings, and disappearance of inclusion bodies on
iopsy.56 Although a subsequent maintenance regimen is
equired therapy for CMV retinitis, there is debate about
ontinued maintenance therapy for patients with GI
MV. Relapse rates of 9 weeks to 1 year for CMV GI tract
isease have been reported fueling this controversy, but
imited studies have shown no benefit for maintenance
herapy.56 Maintenance therapy is considered if patients
ontinue to have symptoms despite a complete course of
herapy or if a patient has recurring disease. The need for
aintenance therapy may be negated with the introduc-
ion of HAART to the patient’s medication regimen.
IDS patients with CMV retinitis on HAART have been
hown to have fewer relapses, continued CMV viral sup-
ression, and in most cases have been able to discontinue
aintenance therapy completely.57 All of these factors,
oupled with improved survival, point to HAARTs inte-
ral position in the treatment of CMV infection of the GI
ract. The appropriate time for initiating HAART in pa-
ients with GI CMV disease is a source of controversy.
nfortunately, there are limited data available on this aubject. Given the theoretical risk of developing immune
econstitution syndrome many clinicians advocate delay-
ng HAART until the acute symptoms of disease resolve
ith CMV therapy. Conversely, some clinicians argue
hat starting HAART alone in patients with mild to
oderate CMV GI disease is a safe and reasonable first
tep rather than initially starting with directed CMV
herapy. Once again, data on this therapeutic strategy are
acking.37 The timing of HAART and/or CMV therapy
hould be made after careful consideration of the pa-
ient’s clinical status as well as communicating with the
atient’s primary HIV physician about potential HAART
nitiation.
In the past several years, oral valganciclovir has ap-
eared as an attractive regimen in place of the intrave-
ous forms of ganciclovir and foscarnet. Currently, no
andomized controlled trials comparing valganciclovir
ith either ganciclovir or foscarnet for treatment of CMV
I disease have been performed. Encouraging evidence
or the treatment of CMV retinitis58 and CMV disease in
olid organ transplantation59 has prompted some physi-
ians to consider using it as initial therapy. Given this
ndirect evidence some societies have recommended the
se of oral valganciclovir for therapy unless symptoms
revent a patient from taking oral medications and/or if
ymptoms are severe enough to result in intestinal mal-
bsorption and thus decrease drug bioavailability.37
astly, there are limited data on approaches to patients
ith treatment failures for GI CMV; again, the majority
f studies on this topic deal with CMV retinitis. Potential
ptions include beginning chronic maintenance therapy
ith the initial drug used or valganciclovir, optimizing
AART to ensure adequate restoration of cellular immu-
ity, changing to an alternative drug that was not used in
he initial regimen, and as a last resort using combina-
ion therapy of ganciclovir and foscarnet.37,60
There are numerous bacterial infections that occur
ore frequently and with a more virulent pattern in HIV
atients. These include Salmonella, Shigella, Campy-
obacter jejuni, and, in the age of HIV prophylaxis and
idespread use of antibiotics, Clostridium difficile. In fact,
difficile–associated diarrhea now ranks as the most com-
on bacterial infection observed in HIV patients with
iarrhea.61 However, in the realm of GI OIs, mycobacte-
ial diseases, specifically Mycobacterium avium complex
MAC) and Mycobacterium tuberculosis (TB), have a pre-
ominant role.
An HIV-infected patient with GI MAC usually has
isseminated disease, a very low CD4 T-cell count, and
limited survival time. With the introduction of HAART
s well as prophylaxis, the incidence and prevalence of
isseminated MAC has decreased.62 Over the years, MAC
reatment has evolved into a multidrug course of antibi-
tics with a prolonged, and at times indefinite, period of
herapy. Initial, first-line treatment for MAC consists of 2
ntibiotics: clarithromycin and ethambutol. Each agent
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May 2009 AIDS ENTEROPATHY 1961lone has high rates of drug resistance, whereas a com-
ination of the 2 results in complete microbiologic re-
ponse, lower relapse rates, improved clinical symptoms,
nd overall better survival.63,64 The addition of a third
gent, rifabutin, has shown increased survival times, with
he added benefit of less resistance and also can be added
o the earlier-described treatment armamentarium.65
astly, the 2008 National Institutes of Health/Centers for
isease Control/HIV Medicine Association of the Infec-
ious Diseases Society of America guidelines recommend
he addition of either injectable amikacin or streptomy-
in to therapy for patients at high risk of death from
AC, which include patients with CD4 T-cell counts of
0 cells/L or less, high mycobacterial loads, or in the
bsence of HAART.37 Unfortunately, MAC treatment is
ifelong or until immune function has improved with
AART. Many clinicians and societies advocate delaying
he initiation of HAART (in a patient who is HAART-
aive) until a few weeks after MAC therapy has begun.
he goal in delaying HAART therapy is several-fold and
ncludes reducing drug interactions, increasing medica-
ion compliance, and avoiding complications of the im-
une reconstitution syndrome (for a more thorough
eview of the immune reconstitution syndrome and its
ole in MAC therapy as well as other opportunistic in-
ections please see the 2008 National Institutes of
ealth/Centers for Disease Control/HIV Medicine Asso-
iation/Infectious Diseases Society of America TB treat-
ent guidelines for OI infections).37,66,67 Lastly, newer
djuvant regimens consisting of interferon- injections
n pulmonary MAC patients have had promising results.
he addition of interferon- results in higher response
ates, earlier improvement in symptoms, and significantly
ess disease-related deaths compared with the current
tandard of care.68 Unfortunately, there have not been
ny clinical trials to test the effects of interferon- in
atients with disseminated MAC.
TB of the GI tract can affect both the immunocompro-
ised and immunocompetent patient. GI TB accounts for
%–3% of all TB cases worldwide, but represents less than
% of all TB cases in the United States.69 Commonly found
n the region of the ileocecal valve, TB of the GI tract can be
ound almost anywhere, coexists 50% of the time with
ulmonary TB, andmimics a variety of other infectious and
nflammatory conditions of the GI tract.70 The treatment of
ntestinal TB is similar to that of pulmonary and other
xtrapulmonary forms of TB in terms of the regimen used,
esting for drug susceptibility, and ensuring complete pa-
ient adherence to the treatment regimen. Although there
ave been only a few studies on abdominal TB treatment,
hey have confirmed that a multidrug regimen for a mini-
um of 6 months is effective therapy in terms of a micro-
iological and clinical response.71,72 The current recom-
ended regimen for HIV-positive patients consists of
thambutol, rifampin (or rifabutin), isoniazid, and pyraza-
imide for a 2-month initiation phase followed by a t-month continuation phase with isoniazid and rifampin
or rifabutin).37,73 The duration of therapy can vary in HIV
atients, depending on the functionality of their immune
ystem, drug susceptibility, and improvement in clinical
ymptoms. Although surgery was common in the past,
oday it is reserved for patients with complications that do
ot respond to medical therapy and include obstruction,
trictures, abscesses, and perforations. Other alternative reg-
mens and medications have been studied and proposed for
atients with medication intolerance, drug susceptibility,
AART-TB drug interactions, initiation of HAART, treat-
ent failure regimens, and recurrence of disease (see the
008 National Institutes of Health/Centers for Disease
ontrol/HIV Medicine Association/Infectious Diseases So-
iety of America TB treatment guidelines for a more com-
rehensive discussion).37
Nonspecific Treatments for AIDS-
Related Diarrhea
What can we offer patients with AIDS-associated
iarrhea when all specific targeted therapies have been
xhausted? Wilcox and Saag74 have shown that HAART
an suppress patients’ viral load to an undetectable range
nd stop further destruction of CD4 T lymphocytes.
he course of diarrheal disease is reversed dramatically in
ost, but not all, patients who are compliant with treat-
ent. However, for many patients, HAART does not
everse the course of the diarrhea and a systematic rea-
onable algorithm should be undertaken (Figure 4).
Many patients with AIDS-related diarrhea are severely
alnourished and/or have recurrent dehydration. Elemen-
al diets are sometimes helpful, particularly those that con-
igure 4. Proposed treatment algorithm for patients with AIDS and
hronic diarrhea.ain medium-chain triglycerides. The use of short-term hy-
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1962 CELLO AND DAY GASTROENTEROLOGY Vol. 136, No. 6eralimentation, whether by alimentary or intravenous
outes, may be needed early in treatment programs regard-
ess of initiation of HAART. Occasionally, multivitamin and
ineral deficiencies are detected and likewise need to be
orrected by proper supplementation.
A careful analysis of stool samples is an essential and
bligatory first diagnostic step. If an enteric pathogen is
solated, the patient should be treated as appropriately as
ossible with available agents, as outlined earlier (Table
). If after exhaustive stool studies no pathogen is iso-
ated, and no other factors are believed to be contributing
o the diarrheal disease, then there is clearly a role for
dditional, invasive endoscopic evaluations, particularly
n those patients who have very severe refractory, dehy-
rating diarrhea. The decision to perform a complete GI
valuation, consisting of upper endoscopy, small-bowel
iopsies, and colonoscopy with biopsies, must be made in
onjunction with the patient and their primary care pro-
iders. Given the innumerable endoscopic modalities
vailable in gastroenterology and the sophistication of
ost pathology laboratories, there is little reason to
void or refuse invasive diagnostic testing in patients
ho could benefit from targeted therapy.
Surprisingly, but rarely, patients with profound wa-
ery diarrhea and malnutrition will be found to be
ngesting agents, either inadvertently or surrepti-
iously, that are associated with diarrhea. These cathar-
ics include lactose, sorbitol, mannitol, or even over-
he-counter cathartics in their diet. These agents
learly should be considered, proscribed, and their
ntake must be eliminated. Also, it is worthwhile to
xtensively review a patient’s HAART regimen because
any HAART medications, and in particular the pro-
ease inhibitors such as nelfinavir, fosamprenavir, and
itonavir, are well known to cause diarrhea.
Antimotility agents (loperamide, diphenoxylate, codeine)
nd adsorbents (bismuth subsalicylate and kaolin/pectin)
re widely available, generally attempted, and somewhat
elpful in treating mild to moderate diarrhea.75 The GI
ntimotility agents are universally opioids, which decrease
tool output by decreasing GI motility and increase transit
ime, thus generally promoting fluid and electrolyte absorp-
ion.75 These antimotility and adsorbent drugs are all rea-
onably helpful in patients with mild to moderate patho-
en-negative diarrhea. There is insufficient evidence to
upport the routine use of probiotics and/or herbal reme-
ies in AIDS patients with severe diarrhea.76 Most patients
ill have tried several or all of the agents described earlier
efore seeking medical attention. Additional nonstandard
herapies run the gamut of nonsteroidal anti-inflammatory
rugs, clonidine, tincture of opium, and octreotide.
Many clinical studies have evaluated octreotide in pa-
ients with AIDS-related diarrhea.77,78 These studies have
anged in size from 4 to 125 patients. The overall clinical
esponse rates to subcutaneous octreotide range from
5% to 40% in most studies. In our study of 129 patients rho had extensive investigations of their refractory diar-
hea, one third of patients ultimately were found to have
ryptosporidium infections, again highlighting how im-
ortant this organism is in the development of refractory
iarrhea. Nearly one third of the patients in this study
ad true idiopathic diarrhea in which no pathogen was
dentified by stool studies or by endoscopic examination.
n a double-blind, placebo-controlled trial, patients were
ssigned randomly to groups that were given octreotide
00 mcg, 200 mcg, or 300 mcg, or placebo 3 times a day.
t the end of the trial, there were arithmetic, but not
tatistically significant, differences between the groups.
atients with idiopathic diarrhea appeared to fare better
han those with an identifiable pathogen, although the
ifference was not statistically significant. In patients
ho were given octreotide, 45% had achieved control of
heir diarrheal symptoms, compared with 33% of the
lacebo group. Nor was there a significant difference
etween groups with respect to stool frequency during
he double-blind phase. When the trial was extended to 8
eeks during an open-label phase (Figure 5), there was a
ignificant reduction in stool weight between weeks 1
nd 8. With respect to stool frequency, there was no
ifference observed between the groups given octreotide
nd those given placebo during the controlled trial, but
hen the trial was extended during the open-label phase,
nd the patient data were compared with their own
aseline statistics, there was a significant decrease in stool
requency.78
In conclusion, refractory diarrhea is a complex prob-
em among patients with HIV disease. Investigations
hould occur early in the disease course and include a
areful medical history and physical examination, as
ell as stool studies, basic laboratory analyses of in-
ection, nutritional status, and electrolyte derange-
ents, and potentially more-invasive endoscopic and
igure 5. Change in stool weight of patients with AIDS and refractory
iarrhea using octreotide vs placebo in a double-blind phase and open-
abel phase clinical trial. Reprinted with permission from Simon et al.78adiographic evaluations. The etiology of AIDS refrac-
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May 2009 AIDS ENTEROPATHY 1963ory diarrhea is vast and can encompass the same
pectrum of chronic diarrheal diseases that inflict
on–HIV-infected patients as well as other etiologies
uch as infections and medications that are specific to
IV or immunocompromised patients. An interesting
ntity known as AIDS enteropathy has emerged and
volved over the years and reflects an idiopathic,
athogen-negative diarrhea whose underlying cause
ight involve undiscovered infectious pathogen(s), in-
ammatory changes within the GI tract caused by HIV
r other environmental/infectious agents, HIV itself,
r a complex interplay among any one of these etiol-
gies. AIDS refractory diarrhea can pose diagnostic
nd treatment challenges. HAART, nutritional supple-
entation, electrolyte replacements, targeted therapy
or specific infections, and alleviation of symptoms are
ll key elements in the treatment regimen for these
atients. The overall care of these challenging patients,
rom diagnosis to treatment, also involves effective
ommunication and teamwork among a variety of
edical and surgical specialties.
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